Market Cap : 34.52 B | Enterprise Value : 36.23 B | PE Ratio : 47.76 | PB Ratio : 3.17 |
---|
NAS:ILMN has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NAS:ILMN has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Debt-to-EBITDA measures a company's ability to pay off its debt.
Illumina's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2022 was $571 Mil. Illumina's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2022 was $2,044 Mil. Illumina's annualized EBITDA for the quarter that ended in Mar. 2022 was $948 Mil. Illumina's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2022 was 2.76.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's
The historical rank and industry rank for Illumina's Debt-to-EBITDA or its related term are showing as below:
During the past 13 years, the highest Debt-to-EBITDA Ratio of Illumina was 2.93. The lowest was 1.08. And the median was 1.76.
The historical data trend for Illumina's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Illumina's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Diagnostics & Research industry and Healthcare sector, Illumina's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Illumina's Debt-to-EBITDA falls into.
Debt-to-EBITDA measures a company's ability to pay off its debt.
Illumina's Debt-to-EBITDA for the fiscal year that ended in Dec. 2021 is calculated as
Debt-to-EBITDA | = | Total Debt | / | EBITDA | ||
= | (Short-Term Debt & Capital Lease Obligation | + | Long-Term Debt & Capital Lease Obligation) | / | EBITDA | |
= | (71 | + | 2469) | / | 1196 | |
= | 2.12 |
Illumina's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2022 is calculated as
Debt-to-EBITDA | = | Total Debt | / | EBITDA | ||
= | (Short-Term Debt & Capital Lease Obligation | + | Long-Term Debt & Capital Lease Obligation) | / | EBITDA | |
= | (571 | + | 2044) | / | 948 | |
= | 2.76 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Mar. 2022) EBITDA data.
In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's
Thank you for viewing the detailed overview of Illumina's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Frank John Edward | officer: Chief Public Affairs Officer | 5200 ILLUMINA WAY SAN DIEGO CA 92122 |
Rollins Carissa | officer: SVP, Chief Information Officer | 5200 ILLUMINA WAY SAN DIEGO CA 92122 |
Pegels Kevin Carl | officer: Chief of Global Operations | 5200 ILLUMINA WAY SAN DIEGO CA 92122 |
Torres Jose | officer: VP, Chief Accounting Officer | 1300 W. 120TH AVENUE WESTMINSTER CO 80234 |
Reeves Kathryne Gambrell | officer: SVP, Chief Marketing Officer | 5200 ILLUMINA WAY SAN DIEGO CA 92122 |
Aravanis Alexander | officer: SVP, Chief Technology Officer | 5200 ILLUMINA WAY SAN DIEGO CA 92122 |
Gottlieb Scott | director | MOLECULAR INSIGHT PHARMACEUTICALS 160 SECOND STREET CAMBRIDGE MA 02142 |
Febbo Phillip G. | officer: SVP Chief Medical Officer | C/O GENOMIC HEALTH, INC. 301 PENOBSCOT DRIVE REDWOOD CITY CA 94063 |
Tousi Susan H | officer: SVP Product Development | 5200 ILLUMINA WAY SAN DIEGO CA 92122 |
Goswami Joydeep | officer: SVP Corp Business Development | SUMITOMO FUDOSAN MITA TWIN BLDG EAST WING 4-2-8 SHIBAURA MINATO-KU TOKYO M0 1080023 |
Siegel Susan E | director | 3000 SAND HILL ROAD BLDG 3 STE 290 MENLO PARK CA 94025 |
Ragusa Robert P | officer: SVP, Global Quality & Ops | |
Hoyt Aimee L | officer: SVP, Chief People Officer | 5200 ILLUMINA WAY SAN DIEGO CA 92122 |
Guthart Gary S | director | C/O INTUITIVE SURGICAL INC 1266 KIFER RD SUNNYVALE CA 94086 |
Mcginnis Karen K | officer: VP, Chief Accounting Officer | INSIGHT ENTERPRISES INC 1305 WEST AUTO DRIVE TEMPE AZ 85284 |
From GuruFocus
By PRNewswire 02-21-2022
By PRNewswire 12-23-2021
Other Sources
By Fool 2022-01-23
By Zacks 2022-01-07
By Zacks 2021-12-27
By Zacks 2022-02-16
By Seekingalpha 2022-03-07
By Zacks 2022-01-24
By Zacks 2022-02-11
By Zacks 2022-01-12
By Zacks 2022-01-05
By Zacks 2022-02-10
By Zacks 2022-01-14
By Zacks 2022-02-07
By Zacks 2021-12-15
By tipranks.com 2022-03-02